Protein marker of focal segmental glomerulosclerosis

Abstract

The invention relates to a protein marker of focal segmental glomerulosclerosis, and more specifically relates to an application of a connecting part selectively connected to one or more proteins in preparing a diagnostic reagent in a development process of human focal segmental glomerulosclerosis. The one or more proteins are selected from [alpha]1 antiprotease, alpha albumin, serum albumin, beta-2-microglobulin, ceruloplasmin, fetuin-B, kininogen, serum transferrin, carboxylesterase, immune globulin gamma-2A chain C region, plasminogen, lysosomal acid phosphatase, protein YIPF3, zinc [alpha]2 glycoprotein, alpha-2-HS-glycoprotein, protein AMBP or T cell immune globulin. Specifically, the invention relates to the application of a urine protein potential marker of human focal segmental glomerulosclerosis obtained by a rat model and mass spectrometry.

Description

technical field [0001] The present invention relates to protein markers related to human focal segmental glomerulosclerosis. Specifically, the present invention relates to the use of human focal segmental glomerulosclerosis and disease severity-related protein markers obtained by using adriamycin rat nephropathy model and mass spectrometry analysis. Background technique [0002] Significance of urinary proteomics in kidney disease research: [0003] Unlike blood, which has the ability to maintain homeostasis, urine is more prone to changes, which reflect changes in body functions, that is, urine is an important source of biomarkers, see Youhe G.Can urine be the gold mine for biomarker discovery?. Sci China Life Sci2013; 43. [0004] Urine can often show the function of the urinary system to a certain extent, and it is convenient and simple to use urine changes to diagnose kidney diseases. The functional changes of the urinary system are not easy to detect, and the current...

AI Technical Summary

Problems solved by technology

Current research mainly looks for disease markers by comparing the differences in urine protein groups between the control group and the disease group, which usually reflect the difference in urine protein at a certain time point, which has great limitations, mainly reflected in: (1) In terms of experimental design, for A study of a disease state that does not distinguish between disease severity

There is no complete and comprehensive urine proteomics data to explain the changes in the urine proteome from the beginning of the disease to renal failure, and the course of the disease cannot be diagnosed, so the practicability is not strong

(2) Most of the renal lesions found in clinical patients are in the middle and late stage of the disease, and the obtained biomarkers are mostly reflected in renal failure, which is not very helpful for early diagnosis, early treatment, and improvement of patient survival rate

(3) Before the serological indicators such as blood urea nitrogen and creatinine change, it is not conclusive to use proteomics, a relatively sensitive method, to find markers from urine

(4) There is no clear understanding of the pathophysiological changes of the body during the occurrence and development of the disease

(5) The traditional 2-DE method is mainly aimed at high-abundance proteins, and its application has great limitations and is not comprehensive enough

Images